Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Novartis
Accenture
Cipla
McKinsey
Cantor Fitzgerald
AstraZeneca
Citi
Chinese Patent Office

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,417,191

« Back to Dashboard

Which drugs does patent 6,417,191 protect, and when does it expire?


Patent 6,417,191 protects TRIZIVIR, TRIUMEQ, and EPZICOM, and is included in three NDAs. There have been zero Paragraph IV challenges on Triumeq, Trizivir, and Epzicom.

Protection for TRIZIVIR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in thirty-five countries.

Summary for Patent: 6,417,191

Title: Synergistic combinations of zidovudine, 1592U89 and 3TC
Abstract:The present invention relates to therapeutic combinations of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene- 1-methanol (1592U89), 3'-azido-3'-deoxythymidine (zidovudine) and (2R,cis)-4-amino-]-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin- 2-one (3TC) (or, alternatively to 3TC, (2R,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyr imidin-2-one (FTC)) which have anti-HIV activity. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
Inventor(s): Barry; David Walter (Chapel Hill, NC), St. Clair; Martha Heider (Rougemont, NC)
Assignee: GlaxoSmithKline (Research Triangle Park, NC)
Application Number:08/930,225
Patent Claim Types:
see list of patent claims
Use; Dosage form; Formulation; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Viiv Hlthcare
TRIZIVIR
abacavir sulfate; lamivudine; zidovudine
TABLET;ORAL021205-001Nov 14, 2000ABRXYesYes► Subscribe► Subscribe
Viiv Hlthcare
TRIUMEQ
abacavir sulfate; dolutegravir sodium; lamivudine
TABLET;ORAL205551-001Aug 22, 2014RXYesYes► Subscribe► Subscribe
Viiv Hlthcare
EPZICOM
abacavir sulfate; lamivudine
TABLET;ORAL021652-001Aug 2, 2004ABRXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,417,191

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9506489Mar 30, 1995
United Kingdom9506490Mar 30, 1995
PCT Information
PCT FiledMarch 28, 1996PCT Application Number:PCT/EP96/01352
PCT Publication Date:October 03, 1996PCT Publication Number: WO96/30025

International Patent Family for Patent: 6,417,191

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hungary9801571► Subscribe
Hungary224010► Subscribe
Czech Republic295940► Subscribe
Germany69622386► Subscribe
Germany122005000029► Subscribe
Denmark0817637► Subscribe
Eurasian Patent Organization000626► Subscribe
Estonia9700240► Subscribe
Estonia04047► Subscribe
European Patent Office0817637► Subscribe91171Luxembourg► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Chubb
US Department of Justice
Cerilliant
Argus Health
Chinese Patent Office
Baxter
Boehringer Ingelheim
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot